Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
22. Januar 2019 aktualisiert von: Hoffmann-La Roche
Tocilizumab Real-Life Human Factors Validation Study
This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD).
The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2.
Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
91
Phase
- Phase 4
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Arizona
-
Mesa, Arizona, Vereinigte Staaten, 85202
- Arizona Arthritis and Rheuma
-
-
California
-
Los Alamitos, California, Vereinigte Staaten, 90720
- Valerius Medical Group & Research Ctr of Greater Long Beach
-
Santa Maria, California, Vereinigte Staaten, 93454
- Pacific Arthritis Ctr Med Grp
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40515
- Bluegrass Comm Research, Inc.
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74104
- Oklahoma Center For Arthritis Therapy & Research
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Vereinigte Staaten, 16635
- Altoona Center for Clinical Research
-
Wexford, Pennsylvania, Vereinigte Staaten, 15090
- Advanced Rheumatology & Arthritis Research Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75231
- Metroplex Clinical Research
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Participants with RA for greater than or equal to (>/=6) months receiving 162 mg tocilizumab PFS-NSD for >/=8 weeks and who are suitable for continued treatment at their currently prescribed dose
- CGs and professionally qualified HCPs who are able and willing to administer the injection
Exclusion Criteria:
- RA: Functional status Class IV
- RA: Neuropathies or other conditions that might interfere with pain evaluation
- RA: Pregnant or breastfeeding
- RA: Low neutrophil or platelet count at last laboratory assessment
- RA: Elevated liver enzymes at last laboratory assessment
- Current participation in another interventional clinical trial
- Criteria that might give the participant/CG/HCP an advantage in injection tasks such as employment in the pharmaceutical industry, etc.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Machbarkeit des Geräts
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Caregivers
CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device.
Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Andere Namen:
|
|
Experimental: Healthcare Professionals
HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device.
Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided.
Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Andere Namen:
|
|
Experimental: RA Group 1 (Self-Administration)
Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device.
Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Andere Namen:
|
|
Sonstiges: RA Group 2 (Administration by CG)
CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device.
Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Andere Namen:
|
|
Sonstiges: RA Group 3 (Administration by HCP)
HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device.
Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided.
Visit 1 (Day 0) will be performed by the study nurse.
Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use
Zeitfenster: Day 14
|
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention.
Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use.
Essential tasks included those essential to the execution of the injection.
Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered.
The percentage of participants who successfully performed safety-critical and essential tasks during the first unassisted use (Day 14) was reported.
|
Day 14
|
|
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use
Zeitfenster: Day 28
|
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention.
Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use.
Essential tasks included those essential to the execution of the injection.
Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered.
The percentage of participants who successfully performed safety-critical and essential tasks during the second unassisted use (Day 28) was reported.
|
Day 28
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Who Successfully Performed Ancillary Tasks During First and Second Unassisted Use
Zeitfenster: Days 14, 28
|
Ancillary tasks included those tasks where the potential harm resulting from use error would be minor in severity, or the resultant harms were estimated to occur at sufficiently low levels.
Ancillary tasks included the following: wash hands; clean the injection site with alcohol swab; wait for the alcohol to dry; dispose of the autoinjector cap; inspect full dose delivered after use; dispose of the autoinjector; and treatment of injection site after injection.
The percentage of participants who succesffully performed ancillary tasks during the first (Day 14) and second unassisted use (Day 28) was reported.
|
Days 14, 28
|
|
Visual Analog Scale (VAS) Score for Injection Pain Among Participants With RA
Zeitfenster: 0 and 15 minutes after injection on Days 0, 14, 28
|
Injection pain was assessed on a continuous 100-millimeter (mm) VAS, where 0 mm represents "no pain" and 100 mm represents "unbearable pain".
The mean VAS response at each assessment timepoint was reported among participants with RA.
|
0 and 15 minutes after injection on Days 0, 14, 28
|
|
Percentage of Participants by Response to Categorical Scale of Injection Pain Among Participants With RA
Zeitfenster: 0 and 15 minutes after injection on Days 0, 14, 28
|
Injection pain was assessed on a categorical 6-point Likert scale, ranging from "no pain" to "severe and intolerable".
The percentage of participants was reported by response at each assessment timepoint among participants with RA.
|
0 and 15 minutes after injection on Days 0, 14, 28
|
|
Percentage of Participants by Response to Device Satisfaction Questionnaire
Zeitfenster: Days 0, 14, 28
|
Device satisfaction was assessed using twelve questions on a categorical 5-point Likert scale, ranging from "strongly agree" to "strongly disagree".
Question (Q) 1 (felt the autoinjection was easy to use), Q2 (felt comfortable while using the autoinjector), Q3 (felt the autoinjector was easy to hold), Q4 (able to tell when injection had completed), Q5 (felt he/she can inject properly with the autoinjector), Q6 (felt he/she had control over the injection process), Q7 (felt confident that he/she injected successfully), Q8 (felt it is easy to dispose of the autoinjector), Q9 (autoinjector would help to manage his/her injection schedule), Q10 (liked the look/feel of the autoinjector), Q11 (would recommend the autoinjector to someone else who needed to inject), Q12 (would continue having injections with the autoinjector).
The percentage of participants was reported by response at each assessment among participants with RA, CGs, and HCPs.
|
Days 0, 14, 28
|
|
Tender Joint Count (TJC) Among Participants With RA
Zeitfenster: Baseline (Day 0)
|
Sixty-eight joints were assessed for tenderness among participants with RA.
The number of tender joints at Baseline was reported.
|
Baseline (Day 0)
|
|
Swollen Joint Count (SJC) Among Participants With RA
Zeitfenster: Baseline (Day 0)
|
Sixty-six joints were assessed for swelling among participants with RA.
The number of swollen joints at Baseline was reported.
|
Baseline (Day 0)
|
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Among Participants With RA
Zeitfenster: Days 0, 14, 28
|
Ability to perform daily living activities was assessed across eight component sets including dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities.
Twenty questions were scored on a 4-point Likert scale from 0 meaning "without any difficulty" to 3 meaning "unable to do".
The overall score was computed as the sum of domain scores divided by the number of domains answered.
Therefore, the score range for HAQ-DI was the same as that of the individual questions, that is, from 0 to 3, where 0 indicates "least difficulty" and 3 indicates "extreme difficulty".
The mean change from baseline in HAQ-DI at each assessment was reported among participants with RA.
|
Days 0, 14, 28
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
21. März 2016
Primärer Abschluss (Tatsächlich)
29. Juli 2016
Studienabschluss (Tatsächlich)
29. Juli 2016
Studienanmeldedaten
Zuerst eingereicht
11. Februar 2016
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
11. Februar 2016
Zuerst gepostet (Schätzen)
15. Februar 2016
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
19. April 2019
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
22. Januar 2019
Zuletzt verifiziert
1. Januar 2019
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- WA29917
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Ja
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .